01 Integration of CRISPR-based Point-of-Care Molecular Diagnostics CRISPR-enabled molecular diagnostics are gaining traction as next-generation point-of-care solutions by delivering laboratory-grade sensitivity without complex instrumentation. These systems use gene-editing enzymes to identify pathogen-specific genetic sequences within minutes, supporting rapid infectious disease detection in resource-limited settings. Companies including Mammoth Biosciences and Sherlock Biosciences are advancing CRISPR-based diagnostic platforms, accelerating the shift toward portable, highly sensitive infectious disease testing.
02 Shift toward Syndromic Multiplex Point-of-Care Panels Syndromic multiplex testing is emerging as a key market trend in the infectious disease point-of-care diagnostics market, enabling simultaneous detection of multiple respiratory, gastrointestinal, and bloodstream pathogens from a single sample. This reduces diagnostic uncertainty and supports targeted treatment decisions. In January 2025, QIAGEN announced that its QIAstat-Dx respiratory panel demonstrated the ability to identify over 20 viral and bacterial respiratory targets in a single test run, supporting faster clinical triage and antimicrobial stewardship programs as healthcare systems increasingly prioritize comprehensive near-patient pathogen identification.
01 Growing Need for Antimicrobial Stewardship and Expansion of Decentralized Infectious Disease Testing Networks Drives Market Increasing global focus on antimicrobial stewardship programs is accelerating adoption of infectious disease point-of-care diagnostics. Rapid pathogen identification helps clinicians differentiate bacterial from viral infections, reducing unnecessary antibiotic prescriptions and supporting targeted treatment decisions. The European Centre for Disease Prevention and Control reported in 2025 that antimicrobial resistance continues to cause more than 35,000 deaths annually across the European Union and European Economic Area, reinforcing the need for rapid diagnostic tools that enable evidence-based antimicrobial use, improved infection management outcomes, and sustained market growth.The rapid expansion of decentralized healthcare delivery models is a major market driver for infectious disease point-of-care diagnostics. Healthcare systems are increasingly shifting diagnostic services from centralized laboratories to community clinics, pharmacies, urgent care centers, and mobile health units to improve testing accessibility and reduce result turnaround times. This is creating sustained demand for compact, rapid, and easy-to-operate diagnostic platforms capable of delivering accurate infectious disease results directly at the point of care across diverse healthcare environments globally.
01 Specimen Quality Variability in Decentralized Testing and Maintaining Quality Control Outside Laboratory Infrastructure Restrain Market Expansion Infectious disease point-of-care diagnostics frequently depend on specimens collected outside controlled laboratory environments, creating challenges related to sample quality and consistency. Variations in swab collection techniques, sample volume, storage conditions, and operator experience can affect diagnostic accuracy and result reliability. Since many point-of-care tests are used in pharmacies, community clinics, and remote healthcare settings, maintaining standardized specimen collection practices remains difficult, limiting confidence in test outcomes and restraining broader market adoption.Unlike centralized laboratories that operate under tightly controlled quality management systems, point-of-care diagnostics are frequently deployed across pharmacies, physician offices, mobile clinics, and rural healthcare facilities. Ensuring routine calibration, quality control checks, operator competency, and compliance with testing protocols across thousands of decentralized locations remains challenging. Variability in operational practices can affect test reliability and increase oversight requirements, creating a significant restraint for large-scale deployment of infectious disease point-of-care diagnostic systems.
01 Integration into Community Pharmacy Testing and Development of Wastewater-Linked POC Surveillance Solutions Offer Growth Opportunities to Market Players The expansion of pharmacist-led testing services is creating growth opportunity for infectious disease point-of-care diagnostics manufacturers. Community pharmacies are increasingly becoming frontline diagnostic access points for respiratory and seasonal infections, reducing pressure on hospitals and clinics. In 2025, the UK National Health Service expanded Pharmacy First services nationwide, enabling participating pharmacies to manage multiple common infectious conditions, supporting wider deployment of rapid near-patient diagnostic technologies across community healthcare settings.Growing emphasis on localized outbreak monitoring is creating opportunities for point-of-care diagnostic systems integrated with environmental surveillance programs. Healthcare authorities increasingly seek rapid testing solutions that complement wastewater-based pathogen monitoring by providing immediate community-level infection confirmation. This approach supports faster outbreak containment, targeted public health interventions, and decentralized disease surveillance. Manufacturers capable of linking rapid diagnostics with real-time epidemiological monitoring frameworks can access emerging opportunities within public health preparedness and infectious disease response programs.
December 2025 Roche received FDA clearance and CLIA waiver for cobas liat Bordetella molecular point-of-care test.
October 2025 Sysmex signed an exclusive distribution and supply agreement with QIAGEN for infectious disease diagnostic products in Japan.
September 2025 Molbio Diagnostics expanded its Truenat point-of-care molecular diagnostics platform to over 85 countries.
September 2025 QuidelOrtho launched QUICKVUE Influenza + SARS Test for professional point-of-care respiratory testing in the US.
September 2025 QIAGEN received US FDA clearance for QIAstat-Dx Rise, expanding automated syndromic infectious disease testing in the US.